A screenshot of a Webex meeting showing the main speaker, Maurice Hampton, with tiles at the top of the rest of the panel

The 2020 Technology Showcase was Maurice Hampton’s second time at the annual event, but his first opportunity to announce a collaboration that wouldn’t have been possible without it.  

A diagram  showing both chemical makeup and graphic depiction of different cells and molecules.

A team of researchers at the Frederick National Laboratory for Cancer Research (FNL) has developed a nanotechnology platform which targets the lymphatic system, an approach that could provide more effective treatment and therapies against infectious diseases and cancer. 

A screenshot taken during a presentation showing a slide about the panel's topic and a woman's video sharing in the top right corner

The 2020 Technology Showcase on September 9 brought well over 300 viewers for a half-day of presentations and panels on technology commercialization and collaboration. The annual event once again highlighted the capabilities of the Frederick National Laboratory for Cancer Research (FNL), National Cancer Institute (NCI), and greater Frederick region—but this year, with its novel virtual format, it reached a new audience. Attendees logged in from all over the world, including the United Kingdom, Switzerland, Brazil, Malaysia, and China. It was a first for the typically regional event.

By investigating the biological structure of a protein known to cause a genetic skin condition, scientists at the Frederick National Laboratory for Cancer Research validated a decades-old hypothesis about disease implications surrounding the protein’s mutation in a recent study published

Just a few years ago, it was difficult to get any meaningful sequence data from formalin-fixed, paraffin-embedded (FFPE) patient samples.  

The ATOM preclinical drug discovery workflow.

The Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, an initiative that aims to expedite research and development for new medicines, is making headway. 

Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates.

Chimeric antigen receptor or CAR T-cell therapy is FDA approved to treat patients with blood cancers including non-Hodgkins lymphoma and acute lymphoblastic leukemia, whose disease persists or returns following first-line treatments. One reason CAR T-cell therapy is effective is because a patient’s blood contains an abundance of the cancer cells that stimulate the activation and expansion of the modified T-cells. 

The old adage that says two heads are better than one certainly seems true for Mitchell Ho, Ph.D., a senior investigator in the Center for Cancer Research (CCR), and Xiaolin Wu, Ph.D., a principal scientist in the Genomics Technology Laboratory, a CCR Core at the Frederick National Laboratory.

The Frederick National Laboratory’s Nanotechnology Characterization Laboratory recently supported a first-of-its-kind study examining whether nanoparticles used for drug delivery, vaccines, and biomedical imaging were toxic over an extended period of time. 

Cancer cells mutate as they spread, increasing the chance that some may become resistant to treatment. A diagram showing how the genetic mutation of the primary tumor affects metastic sites.

Results from genomic testing of a cancer patient’s biopsy tissue can help guide treatment decisions, depending on the types of gene mutations found. But as it spreads or stops responding to treatment, the cancer changes and develops new mutations. Insights gained from the biopsy of the primary tumor may no longer be relevant in determining next steps.